Nov-19 -

Brain Group

EORTC 1410 – INTELLANCE 2: ABT 414 alone or ABT 414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma.

A randomized phase II study of the EORTC Brain Tumor Group.

EORTC study comparing two treatment regimens for patients with recurring glioblastoma. About 50% of patients with recurrent glioblastoma (rGBM) have tumors with epidermal growth factor receptor (EGFR), which increases tumor growth. Results showed that adding the antibiotic drug ABT414 to the standard chemotherapy with temozolomide (TMZ), was an effective treatment in patients with EGFR amplified recurrent glioblastoma, especially in patients relapsing well after the end of first-line TMZ treatment.


Go to Top